



## **NeuroEM Therapeutics Secures over Half Million Dollars in Funding to Perform Clinical Trial Testing It's Medical Device for Alzheimer's Disease**

### **In-home head device to provide daily electromagnetic treatment to Alzheimer's patients**

Phoenix, AZ (February 19<sup>th</sup>, 2016) Phoenix-based NeuroEM Therapeutics announced today that it has secured over half a million dollars in funding from a private source to carry out a Phase I clinical trial in Alzheimer's patients. The trial will evaluate the safety and preliminary efficacy of the company's proprietary electromagnetic technology through a head device it is developing for in-home treatment.

The clinical trial, which should start by early Fall, will be performed jointly at the Banner Sun Health Research Institute and Banner Alzheimer's Institute in Phoenix. Alzheimer's patients will be treated with Transcranial Electromagnetic Treatment (TEMT) through a novel head device that will provide daily, in-home treatment with complete mobility. The patient's caregiver will administer and oversee the twice daily 1-hour TEMT sessions.

"NeuroEM is honored that this private funding source believes TEMT holds sufficient promise against Alzheimer's Disease to warrant their support of this important clinical trial", said Dr. Gary Arendash, the company's Founder and CEO. "The funding source wishes to be anonymous at the present time since its policy is to seek out and support research having high impact potential against Alzheimer's Disease without the source being inundated by investigator-initiated funding requests. Each year, the private funding source selects one or two research efforts to support.

"Since clinical trials with drugs against Alzheimer's Disease have been universally disappointing, it is time to explore alternative therapeutic approaches against the disease." commented Dr. Arendash. The pre-clinical studies he and his colleagues performed over a 5-year period are supportive that their novel TEMT technology could be effective to both protect against and possibly reverse the memory dysfunction of Alzheimer's Disease.

The clinical trial protocol was approved by the Western Institutional Review Board (WIRB) in January, which also designated the company's TEMT head device as a "non-significant risk" (NSR) device. The NSR designation is important since it means that NeuroEM can proceed with its Phase I clinical trial and that FDA approval for an Investigational Device Exemption (IDE) is not required.

In pre-clinical studies, TEMT appears to be disease-modifying against Alzheimer's through several mechanisms. First, it disaggregates small oligomers of a toxic protein (beta-amyloid) within brain cells – it is this toxic protein that many researchers believe initiates Alzheimer's pathogenesis. Second, TEMT acts to increase energy production inside brain cells by

enhancing mitochondrial function – mitochondrial function is dramatically reduced in Alzheimer’s brains, resulting in much-reduced energy production and the eventual death of brain cells.

If NeuroEM’s clinical trials with TEMT are successful in stabilizing or reversing the memory impairment of Alzheimer’s patients, the company believes commercialization of its TEMT head device could occur within 4-5 years. “Alzheimer’s is such a tragic disease for both the patient and their loved ones”, said Dr. Arendash. “Finding an effective therapeutic against this disease would have a huge impact on the lives of millions of Americans”

### **About NeuroEM Therapeutics, Inc.**

NeuroEM Therapeutics is a medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer’s Disease, Traumatic Brain Injury, and Down’s Syndrome. The company is headquartered in Phoenix, AZ, which is a hub of both pre-clinical and clinical investigation into neurodegenerative disorders and diseases. As such, NeuroEM Therapeutics is collaborating with leading institutions in the Phoenix area such as Banner Sun Health Research Institute, Banner Alzheimer’s Institute, and Arizona State University. For more information about NeuroEM Therapeutics, go to [www.neuroem.com](http://www.neuroem.com).

### **Forward-Looking Statements**

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of NeuroEM Therapeutics, are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.